Carcinomas (Including Squamous Cell and Adenocarcinoma)epidemiologyNCT07723365
Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas
An observational study of Carcinomas (Including Squamous Cell and Adenocarcinoma), run by Mohammed VI University Hospital at 1 site in Morocco.
Trial summary
Twenty patients were included, comprising 11 women (55%) and 9 men (45%), with a mean age of 63.1 years. Chronic sun exposure was identified in 18 patients (90%). The lower eyelid was the most commonly affected site in 9 cases (45%). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Carcinomas (Including Squamous Cell and Adenocarcinoma)
- How many people
- 20 participants
- Where
- 1 siteMorocco
- Study dates
- 1 Jan 2023to 1 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Twenty patients were included in the study: 11 women (55%) and 9 men (45%). The mean age at diagnosis was 63.1 ± 22.3 years (range, 16-90 years). Regarding skin phototype, 5 patients (25%) had Fitzpatrick phototype II, 9 patients (45%) had phototype III, and 6 patients (30%) had phototype IV [4]. Most patients reported substantial lifetime sun exposure, often related to outdoor occupational activities such as farming or security work. Overall, chronic sun exposure was identified in 18 patients (90%).The remaining two patients (10%) had limited cumulative sun exposure due to their young age; however, they remained highly susceptible to UV radiation because of a history of xeroderma pigmentosum. Actinic keratosis was noted in one patient (5%), a history of eyelid trauma in one patient (5%), and chronic tobacco use in two patients (10%), both of whom were male. Xeroderma pigmentosum was present in two patients (10%). No history of arsenic exposure or prior radiotherapy was documented in
Who may be able to join
- all patient with carcinoma
Who cannot join
- no exclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas: A Three-Year Retrospective Case Series From Eastern Morocco
Twenty patients were included, comprising 11 women (55%) and 9 men (45%), with a mean age of 63.1 years. Chronic sun exposure was identified in 18 patients (90%). The lower eyelid was the most commonly affected site in 9 cases (45%). Basal cell carcinoma accounted for 15 tumors (75%), followed by squamous cell carcinoma in 5 cases (25%). Wide local excision with histopathological margin control was performed in all patients (20/20, 100%), and orbital exenteration was required in 1 case (5%). Reconstruction was achieved mainly using local flaps in 12 patients (60%). Ectropion occurred in 2 patients (10%). No local recurrence was observed during a mean follow-up of 22 months.
Read the detailed description
This retrospective study was conducted over a three-year period, from January 2023 to December 2025, and included 20 patients with eyelid carcinomas who underwent surgical treatment in the Department of Plastic and Reconstructive Surgery at Mohammed VI University Hospital. Demographic, clinical, histological, therapeutic, and outcome data were analyzed.
- Keywords
- carcinomas, epidemiologie, surgery
- Medical subject headings
- Carcinoma, Adenocarcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| carcinomas | patient with carcinomas |
What is being measured
The primary outcome is the main question the study is designed to answer.
Eyelid carcinomas
Measured: from January 2023 to December 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study start1 Jan 2023
- Primary completion1 Jan 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinomas (Including Squamous Cell and Adenocarcinoma)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mohammed VI University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Younes Oujidi, Mohammed VI University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07723365
- Sponsor's protocol ID
- soufiane
- Acronym
- epidemiology
- Status last verified
- Jul 2026
- First submitted
- 19 Jul 2026
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas: A Three-Year Retrospective Case Series From Eastern Morocco
- ClinicalTrials.gov ID
- NCT07723365
- Acronym / sponsor ID
- epidemiology / soufiane
- Keywords
- carcinomas, epidemiologie, surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Mohammed VI University HospitalUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 1 Jan 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Twenty patients were included, comprising 11 women (55%) and 9 men (45%), with a mean age of 63.1 years. Chronic sun exposure was identified in 18 patients (90%). The lower eyelid was the most commonly affected site in 9 cases (45%). Basal cell carcinoma accounted for 15 tumors (75%), followed by squamous cell carcinoma in 5 cases (25%). Wide local excision with histopathological margin control was performed in all patients (20/20, 100%), and orbital exenteration was required in 1 case (5%). Reconstruction was achieved mainly using local flaps in 12 patients (60%). Ectropion occurred in 2 patients (10%). No local recurrence was observed during a mean follow-up of 22 months.
Detailed description
This retrospective study was conducted over a three-year period, from January 2023 to December 2025, and included 20 patients with eyelid carcinomas who underwent surgical treatment in the Department of Plastic and Reconstructive Surgery at Mohammed VI University Hospital. Demographic, clinical, histological, therapeutic, and outcome data were analyzed.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| carcinomas | – | –patient with carcinomas |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Twenty patients were included in the study: 11 women (55%) and 9 men (45%). The mean age at diagnosis was 63.1 ± 22.3 years (range, 16-90 years). Regarding skin phototype, 5 patients (25%) had Fitzpatrick phototype II, 9 patients (45%) had phototype III, and 6 patients (30%) had phototype IV [4]. Most patients reported substantial lifetime sun exposure, often related to outdoor occupational activities such as farming or security work. Overall, chronic sun exposure was identified in 18 patients (90%).The remaining two patients (10%) had limited cumulative sun exposure due to their young age; however, they remained highly susceptible to UV radiation because of a history of xeroderma pigmentosum. Actinic keratosis was noted in one patient (5%), a history of eyelid trauma in one patient (5%), and chronic tobacco use in two patients (10%), both of whom were male. Xeroderma pigmentosum was present in two patients (10%). No history of arsenic exposure or prior radiotherapy was documented in
Key inclusion criteria (1 listed)
- all patient with carcinoma
Key exclusion criteria (1 listed)
- no exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Eyelid carcinomas
Time frame: from January 2023 to December 2025
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Carcinomas (Including Squamous Cell and Adenocarcinoma)
RecruitingPhase 1
A Study of ZW251 in Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma
RecruitingObservational study
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Carcinomas (Including Squamous Cell and Adenocarcinoma), Neoplasms
Active, not recruiting
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
Non-Small-Cell Lung Carcinoma, Colorectal Cancer
Active, not recruitingPhase 1
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
ER+ Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinomas (Including Squamous Cell and Adenocarcinoma), run by Mohammed VI University Hospital at 1 site in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Eyelid carcinomas (time frame: from January 2023 to December 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.